Dissemin is shutting down on January 1st, 2025

Published in

Taylor & Francis, Expert Opinion on Drug Discovery, 1(6), p. 9-15

DOI: 10.1517/17460441.2011.534454

Links

Tools

Export citation

Search in Google Scholar

Harnessing the Power of Genomics and Immunoinformatics To Produce Improved Vaccines

Journal article published in 2010 by Leonard Moise ORCID, Leslie Cousens, Joanna Fueyo, Anne S. De Groot
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The role of cellular immunity as a mediator of protection against disease is gaining recognition, particularly in regard to the many pathogens for which we presently lack effective vaccines. As a result, there is an ever-increasing need to understand the T cell populations induced by vaccination and therefore T cell epitopes responsible for triggering their activation. Although the characterization and harnessing of cellular immunity for vaccine development is an active area of research interest, the field still needs to rigorously define T cell epitope specificities, above all, on a genomic level. New immunoinformatic epitope mapping tools now make it possible to identify pathogen epitopes and perform comparisons against human and microbial genomic datasets. Such information will help determine whether adaptive immune responses elicited by a vaccine are both pathogen-specific and protective, but not cross-reactive against host or host-associated sequences that could jeopardize self-tolerance and/or human microbiome-host homeostasis. Here, we discuss advances in genomics and vaccine design and their relevance to the development of safer, more effective vaccines.